Search - tctmd.com

Displaying 61 - 79 of 79

Sort: Relevancy | Date

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2016

April 29, 2016

News Daily News

肺栓塞发作后，二级抗凝效果未持续

July 13, 2015

News Daily News

La FDA Aprueba un Fármaco contra la Insuficiencia Cardíaca que Beneficia la Supervivenia

July 13, 2015

News Daily News

FDA批准了一种具有生存优势的心力衰竭药物

July 13, 2015

News Daily News

FDA Approves Heart Failure Drug That Comes With Survival Benefit

July 13, 2015

News Daily News

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

July 13, 2015

News Daily News

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

July 13, 2015

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

News Daily News

心力衰竭会使ACS后的结果恶化，阿哌沙班不能带来益处

January 28, 2015

News Daily News

La IC Empeora los Resultados Post-SCA No observándose Beneficio alguno con Apixaban

January 28, 2015

News Daily News

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

January 28, 2015

News Daily News

Apixaban es Rentable comparado con Warfarina o Aspirina

February 26, 2014

News Daily News

Apixaban Cost-Effective Compared with Warfarin or Aspirin

February 26, 2014

Cost-Effectiveness of Apixaban vs Current Standard of Care for Stroke Prevention in A-fib Patients

Presentation

Cost-Effectiveness of Apixaban vs Current Standard of Care for Stroke Prevention in A-fib Patients

Presenter: Paul Dorian

February 20, 2014

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Presentation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: A.R. Harrington

April 05, 2013

News Daily News

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

July 12, 2012

News Daily News

A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA

July 12, 2012

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Presentation

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Presenter: S. Lee

July 11, 2012

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.